Home Newsfeeds Barclays Maintains Equal-Weight on Casa Systems, Raises Price Target to $3

Barclays Maintains Equal-Weight on Casa Systems, Raises Price Target to $3

Barclays analyst Tim Long maintains Casa Systems (NASDAQ:CASA) with a Equal-Weight and raises the price target from $2.5 to $3.

byBenzinga Newsdesk

March 16, 2023

1 minute read

Barclays analyst Tim Long maintains Casa Systems (NASDAQ:CASA) with a Equal-Weight and raises the price target from $2.5 to $3.

Analyst Ratings

Where Cytek Biosciences Stands With Analysts

By Benzinga Insights

July 14, 5:02 PM

Cytek Biosciences (NASDAQ:CTKB) has observed the following analyst ratings within the last quarter:

CTKB

Rockwell Automation Q3 Adj. EPS $2.66 Beats $2.39 Estimate, Sales $1.97B Miss $2.00B Estimate

By Bill Haddad

July 27, 7:01 AM

Rockwell Automation (NYSE:ROK) reported quarterly earnings of $2.66 per share which beat the analyst consensus estimate of $2.39 by 11.3 percent. This is a 15.15 percent increase over earnings of $2.31 per share from the

ROK

Events
News

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

By Charles Gross

June 2, 6:47 AM

BioNTech SE (NASDAQ:BNTX, &ldquo, BioNTech&rdquo, )) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody

BNTX

News

Earlier Announced, Digital Ally Passes 200 Subscription Milestone For Law Enforcement Orders

By Benzinga Newsdesk

October 25, 1:56 PM

Flexible spending model met with high demand from law enforcement agencies Lenexa, KS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (NASDAQ:DGLY) (the "Company"), today

DGLY

Barclays Maintains Equal-Weight on Casa Systems, Raises Price Target to $3

Related Posts

Where Cytek Biosciences Stands With Analysts

Rockwell Automation Q3 Adj. EPS $2.66 Beats $2.39 Estimate, Sales $1.97B Miss $2.00B Estimate

BioNTech And OncoC4 Present Positive Phase 1/2 Data For Antibody Candidate BNT316/ONC-392 In Hard-to-Treat NSCLC At ASCO

Earlier Announced, Digital Ally Passes 200 Subscription Milestone For Law Enforcement Orders